Lead Product(s): rAAV2-ND4
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
Results of two clinical studies utilizing NFS-01 in the treatment of Leber's Hereditary Optic Neuropathy will be presented in May 2020 at the ASGCT Annual Meeting.